Literature DB >> 994327

Antibacterial activity of efrotomycin.

B M Frost, M E Valiant, B Weissberger, E L Dulaney.   

Abstract

Efrotomycin is a narrow spectrum antibiotic. Among the genera tested for susceptibility in vitro it is most active against isolates of Moraxella, Pasteurella, Yersinia, Haemophilus, Streptococcus and Corynebacterium. The drug is as active by oral administration as by the subcutaneous route. Blood levels rise rapidly to high concentrations, after oral dosing, and are prolonged. Two peaks occur which may indicate biliary excretion and reabsorption. Urinary excretion is minimal. The high blood concentrations explain, in part, the in vivo activity against pathogens such as Bordetella bronchiseptica which are relatively insensitive in vitro. Oral activity of efrotomycin is an advantage over the related antibiotics. X-5108 and mocimycin.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 994327     DOI: 10.7164/antibiotics.29.1083

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  5 in total

1.  Inhibition of bacterial protein synthesis by elongation-factor-Tu-binding antibiotics MDL 62,879 and efrotomycin.

Authors:  P Landini; M Bandera; B P Goldstein; F Ripamonti; A Soffientini; K Islam; M Denaro
Journal:  Biochem J       Date:  1992-05-01       Impact factor: 3.857

Review 2.  A brief history of antibiotics and select advances in their synthesis.

Authors:  Kyriacos C Nicolaou; Stephan Rigol
Journal:  J Antibiot (Tokyo)       Date:  2017-07-05       Impact factor: 2.649

Review 3.  Biology of Bordetella bronchiseptica.

Authors:  R A Goodnow
Journal:  Microbiol Rev       Date:  1980-12

Review 4.  Antimicrobial growth promoters used in animal feed: effects of less well known antibiotics on gram-positive bacteria.

Authors:  Patrick Butaye; Luc A Devriese; Freddy Haesebrouck
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

5.  Bioconversion capacity of Streptomyces sp GE44282, a producer of the antibiotics heneicomycin and aurodox.

Authors:  F Marinelli; S Stella; N Montanini; F Le Monnier; L Cavaletti; E Selva
Journal:  J Ind Microbiol       Date:  1995-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.